Rosuvastatin Reduces Blood Viscosity in Patients with Acute Coronary Syndrome.
10.4070/kcj.2016.46.2.147
- Author:
Lae Young JUNG
1
;
Sang Rok LEE
;
Jin Mu JUNG
;
Yi Shik KIM
;
Sun Hwa LEE
;
Kyoung Suk RHEE
;
Jei Keon CHAE
;
Dong Hwan LEE
;
Dal Sik KIM
;
Won Ho KIM
;
Jae Ki KO
Author Information
1. Division of Cardiology, Chonbuk National University Hospital and Chonbuk National University Medical School, Jeonju, Korea. medorche@jbnu.ac.kr
- Publication Type:Original Article
- Keywords:
Blood viscosity;
Rheology;
Acute coronary syndrome;
Rosuvastatin
- MeSH:
Acute Coronary Syndrome*;
Angina, Unstable;
Atherosclerosis;
Blood Viscosity*;
Cholesterol;
Follow-Up Studies;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Lipoproteins;
Male;
Myocardial Infarction;
Prospective Studies;
Rheology;
Rupture;
Rosuvastatin Calcium
- From:Korean Circulation Journal
2016;46(2):147-153
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: Wall shear stress contributes to atherosclerosis progression and plaque rupture. There are limited studies for statin as a major contributing factor on whole blood viscosity (WBV) in patients with acute coronary syndrome (ACS). This study investigates the effect of statin on WBV in ACS patients. SUBJECTS AND METHODS: We prospectively enrolled 189 consecutive patients (mean age, 61.3±10.9 years; 132 males; ST-segment elevation myocardial infarction, n=52; non-ST-segment elevation myocardial infarction, n=84; unstable angina n=53). Patients were divided into two groups (group I: previous use of statins for at least 3 months, n=51; group II: statin-naïve patients, n=138). Blood viscosities at shear rates of 1 s-1 (diastolic blood viscosity; DBV) and 300 s-1 (systolic blood viscosity; SBV) were measured at baseline and one month after statin treatment. Rosuvastatin was administered to patients after enrollment (mean daily dose, 16.2±4.9 mg). RESULTS: Baseline WBV was significantly higher in group II ([SBV: group I vs group II, 40.8±5.9 mP vs. 44.2±7.4 mP, p=0.003], [DBV: 262.2±67.8 mP vs. 296.9±76.0 mP, p=0.002]). WBV in group II was significantly lower one month after statin treatment ([SBV: 42.0±4.7 mP, p=0.012, DBV: 281.4±52.6 mP, p=0.044]). However, low-density lipoprotein cholesterol level was not associated with WBV in both baseline (SBV: R2=0.074, p=0.326; DBV: R2=0.073, p=0.337) and after one month follow up (SBV: R2=0.104, p=0.265; DBV: R2=0.112, p=0.232). CONCLUSION: Previous statin medication is an important determinant in lowering WBV in patients with ACS. However, one month of rosuvastatin decreased WBV in statin-naïve ACS patients.
